MRNA Nanomedicine: Design and Recent Applications

Overview

Journal Exploration (Beijing)

Specialty Biomedical Engineering

Date 2022 Oct 17

PMID 36249890

Authors

Luke J Kubiatowicz

Animesh Mohapatra

Nishta Krishnan

Ronnie H Fang

Liangfang Zhang

Affiliations

Soon will be listed here.

Abstract

The rational design and application of mRNA-based medicine have recently yielded some key successes in the clinical management of human diseases. mRNA technology allows for the facile and direct production of proteins in vivo, thus circumventing the need for lengthy drug development cycles and complex production workflows. As such, mRNA formulations can significantly improve upon the biological therapies that have become commonplace in modern medicine. Despite its many advantages, mRNA is inherently fragile and has specific delivery requirements. Leveraging the engineering flexibility of nanobiotechnology, mRNA payloads can be incorporated into nanoformulations such that they do not invoke unwanted immune responses, are targeted to tissues of interest, and can be delivered to the cytosol, resulting in improved safety while enhancing bioactivity. With the rapidly evolving landscape of nanomedicine, novel technologies that are under development have the potential to further improve the clinical utility of mRNA medicine. This review covers the design principles relevant to engineering mRNA-based nanomedicine platforms. It also details the current research on mRNA nanoformulations for addressing viral infections, cancers, and genetic diseases. Given the trends in the field, future mRNA-based nanomedicines have the potential to change how many types of diseases are managed in the clinic.

Citing Articles

Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.

Xu L, Shao Z, Fang X, Xin Z, Zhao S, Zhang H Exploration (Beijing). 2025; 5(1):20230165.

PMID: 40040830 PMC: 11875455. DOI: 10.1002/EXP.20230165.

Basic helix-loop-helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases.

Shao F, Wang Z, Ye L, Wu R, Wang J, Yu Q Burns Trauma. 2025; 13():tkae075.

PMID: 39830193 PMC: 11741524. DOI: 10.1093/burnst/tkae075.

Programmable Macrophage Vesicle Based Bionic Self-Adjuvanting Vaccine for Immunization against Monkeypox Virus.

Lin W, Shen C, Li M, Ma S, Liu C, Huang J Adv Sci (Weinh). 2024; 12(1):e2408608.

PMID: 39513669 PMC: 11714231. DOI: 10.1002/advs.202408608.

Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.

Lu J, Shen X, Li H, Du J Exploration (Beijing). 2024; 4(5):20230142.

PMID: 39439496 PMC: 11491310. DOI: 10.1002/EXP.20230142.

SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop.

Jiang Z, Yang G, Wang G, Wan J, Zhang Y, Song W J Exp Clin Cancer Res. 2024; 43(1):288.

PMID: 39425205 PMC: 11490128. DOI: 10.1186/s13046-024-03206-5.

References

Tsoras A, Champion J . Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications. Annu Rev Chem Biomol Eng. 2019; 10:337-359. DOI: 10.1146/annurev-chembioeng-060718-030347. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Scott C, Vacca F, Gruenberg J . Endosome maturation, transport and functions. Semin Cell Dev Biol. 2014; 31:2-10. DOI: 10.1016/j.semcdb.2014.03.034. View

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J, Karmali P . Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017; 114(10):E1941-E1950. PMC: 5347596. DOI: 10.1073/pnas.1619653114. View

Phua K, Nair S, Leong K . Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale. 2014; 6(14):7715-29. PMC: 4100211. DOI: 10.1039/c4nr01346h. View

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

Haensler J, Szoka Jr F . Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem. 1993; 4(5):372-9. DOI: 10.1021/bc00023a012. View

DeRosa F, Guild B, Karve S, Smith L, Love K, Dorkin J . Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther. 2016; 23(10):699-707. PMC: 5059749. DOI: 10.1038/gt.2016.46. View

Perry J, Reuter K, Luft J, Pecot C, Zamboni W, DeSimone J . Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location. Nano Lett. 2017; 17(5):2879-2886. PMC: 5708115. DOI: 10.1021/acs.nanolett.7b00021. View

10.

Shukla S, Marks I, Church D, Chan S, Pokorski J, Steinmetz N . Tobacco mosaic virus for the targeted delivery of drugs to cells expressing prostate-specific membrane antigen. RSC Adv. 2021; 11(33):20101-20108. PMC: 8180379. DOI: 10.1039/d1ra03166j. View

11.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

12.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

13.

Cheng Q, Wei T, Jia Y, Farbiak L, Zhou K, Zhang S . Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I. Adv Mater. 2018; 30(52):e1805308. DOI: 10.1002/adma.201805308. View

14.

Schott J, Stoecklin G . Networks controlling mRNA decay in the immune system. Wiley Interdiscip Rev RNA. 2011; 1(3):432-56. DOI: 10.1002/wrna.13. View

15.

Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J . Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017; 117(15):10043-10120. PMC: 5611849. DOI: 10.1021/acs.chemrev.7b00042. View

16.

Anselmo A, Mitragotri S . Impact of particle elasticity on particle-based drug delivery systems. Adv Drug Deliv Rev. 2016; 108:51-67. DOI: 10.1016/j.addr.2016.01.007. View

17.

Kim J, Eygeris Y, Gupta M, Sahay G . Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021; 170:83-112. PMC: 7837307. DOI: 10.1016/j.addr.2020.12.014. View

18.

Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K . Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol. 2015; 33(8):870-6. PMC: 4663660. DOI: 10.1038/nbt.3298. View

19.

Dolgin E . The tangled history of mRNA vaccines. Nature. 2021; 597(7876):318-324. DOI: 10.1038/d41586-021-02483-w. View

20.

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View